First Trust Advisors
RYTM icon

First Trust Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

First Trust Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.61M Sell
32,482
-53,024
-62% -$4.79M ﹤0.01% 1744
2026
Q1 		$7.44M Sell
85,506
-2,999
-3% -$292K 0.01% 1240
2025
Q4 		$9.47M Buy
88,505
+7,602
+9% +$806K 0.01% 1122
2025
Q3 		$8.17M Buy
80,903
+7,189
+10% +$667K 0.01% 1158
2025
Q2 		$4.66M Sell
73,714
-16,065
-18% -$984K ﹤0.01% 1383
2025
Q1 		$4.76M Sell
89,779
-28,558
-24% -$1.58M ﹤0.01% 1337
2024
Q4 		$6.62M Buy
118,337
+47,575
+67% +$2.63M 0.01% 1216
2024
Q3 		$3.71M Sell
70,762
-20,248
-22% -$970K ﹤0.01% 1478
2024
Q2 		$3.74M Buy
+91,010
New +$3.63M ﹤0.01% 1423
2023
Q4 		– Sell
-75,315
Closed -$1.73M – 2424
2023
Q3 		$1.73M Buy
75,315
+31,150
+71% +$698K ﹤0.01% 1744
2023
Q2 		$728K Buy
+44,165
New +$797K ﹤0.01% 2054

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

First Trust Advisors's RYTM Position: Q2 2026 in Review

First Trust Advisors reduced its Rhythm Pharmaceuticals (RYTM) stake by 62% in Q2 2026, selling an estimated $4.79M and leaving 32,482 shares worth $3.61M. The position accounts for ﹤0.01% of the portfolio, ranked #1744.

First Trust Advisors first reported a position in RYTM in Q2 2023 and has held it in 11 quarters since. The position peaked at $9.47M in Q4 2025. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • First Trust Advisors held 32,482 shares of Rhythm Pharmaceuticals worth $3.61M as of Q2 2026.
  • First Trust Advisors sold 53,024 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $4.79M.
  • Rhythm Pharmaceuticals made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #1744 holding.
  • First Trust Advisors first reported a position in Rhythm Pharmaceuticals in Q2 2023 and has held it in 11 quarters since.
  • First Trust Advisors's Rhythm Pharmaceuticals position peaked at $9.47M in Q4 2025.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.